Nutriband (NASDAQ: NTRB) has raised approximately $1.75 million through the exercise of 272,671 NTRBW warrants at a strike price of $6.43, according to an announcement by the company. The warrants expired on Sept. 30 without extension, leaving Nutriband with no remaining tradable warrants. The proceeds are primarily earmarked to support the remaining clinical development of AVERSA Fentanyl and the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval.
AVERSA Fentanyl is being developed as a potential first-of-its-kind opioid patch with abuse-deterrent properties. According to a 2022 Health Advances market analysis, the product could achieve estimated peak annual U.S. sales of $80 million to $200 million. The successful development and approval of AVERSA Fentanyl would represent a significant advancement in addressing the ongoing opioid crisis by providing a safer alternative for patients requiring transdermal fentanyl while deterring abuse, misuse, diversion, and accidental exposure.
Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is the abuse-deterrent fentanyl patch incorporating its proprietary AVERSA technology. This technology can be incorporated into any transdermal patch to prevent the abuse of drugs with abuse potential. The company’s website is www.nutriband.com.
The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB. MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. MIR delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics, and diverse industries. It also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
The successful financing comes at a critical time for Nutriband as it prepares to advance AVERSA Fentanyl through the final stages of clinical development and into the regulatory review process. If approved, the product could address a significant unmet need in pain management while mitigating risks associated with opioid abuse. The company’s ability to secure funding through warrant exercises demonstrates continued investor interest in its pipeline. For more information, please visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
